PL2430002T3 - Sposób wytwarzania związku przydatnego jako inhibitor TAFI - Google Patents

Sposób wytwarzania związku przydatnego jako inhibitor TAFI

Info

Publication number
PL2430002T3
PL2430002T3 PL10721758T PL10721758T PL2430002T3 PL 2430002 T3 PL2430002 T3 PL 2430002T3 PL 10721758 T PL10721758 T PL 10721758T PL 10721758 T PL10721758 T PL 10721758T PL 2430002 T3 PL2430002 T3 PL 2430002T3
Authority
PL
Poland
Prior art keywords
tafia
inhibitor
preparation
compound useful
useful
Prior art date
Application number
PL10721758T
Other languages
English (en)
Inventor
Kai Rossen
Volker Kraft
Hermut Wehlan
Antony Bigot
Véronique Crocq-Stuerga
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PL2430002T3 publication Critical patent/PL2430002T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
PL10721758T 2009-05-15 2010-05-11 Sposób wytwarzania związku przydatnego jako inhibitor TAFI PL2430002T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09290366 2009-05-15
EP10721758.0A EP2430002B1 (en) 2009-05-15 2010-05-11 Process for the preparation of a compound useful as an inhibitor of tafia
PCT/EP2010/056426 WO2010130718A1 (en) 2009-05-15 2010-05-11 Process for the preparation of a compound useful as an inhibitor of tafia

Publications (1)

Publication Number Publication Date
PL2430002T3 true PL2430002T3 (pl) 2013-12-31

Family

ID=41259362

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10721758T PL2430002T3 (pl) 2009-05-15 2010-05-11 Sposób wytwarzania związku przydatnego jako inhibitor TAFI

Country Status (22)

Country Link
US (1) US8865906B2 (pl)
EP (1) EP2430002B1 (pl)
JP (1) JP5706397B2 (pl)
KR (1) KR20120016651A (pl)
CN (1) CN102459192B (pl)
AU (1) AU2010247431B2 (pl)
BR (1) BRPI1010571A2 (pl)
CA (1) CA2760748A1 (pl)
CY (1) CY1114493T1 (pl)
DK (1) DK2430002T3 (pl)
ES (1) ES2431068T3 (pl)
HR (1) HRP20130881T1 (pl)
IL (1) IL216202A (pl)
MX (1) MX2011011849A (pl)
MY (1) MY157304A (pl)
PL (1) PL2430002T3 (pl)
PT (1) PT2430002E (pl)
RS (1) RS52963B (pl)
RU (1) RU2538506C2 (pl)
SG (1) SG176558A1 (pl)
SI (1) SI2430002T1 (pl)
WO (1) WO2010130718A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2793523C (en) * 2010-03-18 2015-05-05 Daiichi Sankyo Company, Limited Cyclopropanecarboxylic acid derivative
RU2572814C2 (ru) * 2010-03-18 2016-01-20 Дайити Санкио Компани, Лимитед ЦИКЛОАЛКИЛ-ЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ ИМИДАЗОЛА, ОБЛАДАЮЩЕЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ TAFIa
KR20130130737A (ko) 2010-11-11 2013-12-02 사노피 ３­（６­아미노­피리딘­３일）­２­아크릴산 유도체의 제조방법
EP2782575B1 (en) 2011-11-25 2016-04-20 Sanofi Crystalline salts of r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
US9102657B2 (en) 2011-11-25 2015-08-11 Sanofi Sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid
EP2805705B1 (en) 2013-05-23 2016-11-09 IP Gesellschaft für Management mbH Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
NZ755847A (en) * 2017-03-01 2021-12-24 Boehringer Ingelheim Int Transition metal-catalyzed protodecarboxylation of α-halo-acrylic acid derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4216218A (en) * 1979-02-23 1980-08-05 American Hoechst Corporation Antidepressant and analgesic 4-aryloxy- and 4-arylthio-3-phenylpiperidines
IT1177017B (it) * 1984-10-22 1987-08-26 Ravizza Spa Processo per la preparazione dell'acido 2(4-flurofenil)alfa-metil-5-benzox azoloacetico
TR200101865T2 (tr) * 1998-12-24 2001-12-21 Fujisawa Pharmaceutical Co .Ltd. İmidazol bileşimleri ve onların tıbbi kullanımları.
US8710232B2 (en) 2004-04-22 2014-04-29 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives used as TAFIa inhibitors
DE102004020186A1 (de) 2004-04-22 2005-11-17 Aventis Pharma Deutschland Gmbh Heterocyclylessigsäuren als Inhibitoren von TAFla

Also Published As

Publication number Publication date
CN102459192B (zh) 2015-06-24
JP2012526763A (ja) 2012-11-01
EP2430002B1 (en) 2013-07-24
RU2538506C2 (ru) 2015-01-10
SG176558A1 (en) 2012-01-30
RU2011151044A (ru) 2013-06-20
PT2430002E (pt) 2013-09-11
IL216202A0 (en) 2012-01-31
SI2430002T1 (sl) 2013-10-30
HRP20130881T1 (hr) 2013-10-25
AU2010247431A1 (en) 2011-12-01
MX2011011849A (es) 2011-12-08
CY1114493T1 (el) 2016-10-05
AU2010247431B2 (en) 2015-02-19
CN102459192A (zh) 2012-05-16
WO2010130718A1 (en) 2010-11-18
HK1168102A1 (en) 2012-12-21
IL216202A (en) 2015-07-30
US20120245358A1 (en) 2012-09-27
JP5706397B2 (ja) 2015-04-22
KR20120016651A (ko) 2012-02-24
EP2430002A1 (en) 2012-03-21
ES2431068T3 (es) 2013-11-25
RS52963B (sr) 2014-02-28
DK2430002T3 (da) 2013-11-04
BRPI1010571A2 (pt) 2019-09-24
US8865906B2 (en) 2014-10-21
MY157304A (en) 2016-05-31
CA2760748A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
HRP20170255T1 (hr) Postupak za pripremu spojeva korisnih kao inhibitori sglt-a
PT3604299T (pt) Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase
IL219094A0 (en) Process for the preparation of compounds useful as inhibitors of sglt2
ZA201200409B (en) Compounds for the reduction of b-amyloid production
IL241744A0 (en) Preparations and methods for producing a compound
IL213052A0 (en) Benzonaphtyridine compounds used as inhibitors of autotaxin
IL227812A0 (en) A compound of a derivative of cyclopentyl acrylic acid
EP2504343A4 (en) HEPATITIS C INHIBITOR COMPOUNDS
IL216202A0 (en) PROCESS FOR THE PREPARATION OF A COMPOUND USEFUL AS AN INHIBITOR OF TAFIa
ZA201100694B (en) Salts of hiv inhibitor compounds
ZA201300154B (en) Crystalline form of a 3-phenoxymethylpyrrolidine compound
ZA201104319B (en) Crystalline forms of a 3-carboxypropyl-aminotetralin compound
IL217139A0 (en) Process for the preparation of arylpyridinyl compounds
EP2291077A4 (en) METHOD OF MANUFACTURING RHO-KINASE INHIBITOR COMPOUNDS
IL220231A0 (en) A process for the preparation of thio-triazolyl group containing compounds
GB0905895D0 (en) Process for the preparation of chalcogenone compounds
SI2307435T1 (sl) Soli spojin, inhibitorjev HIV
GB0904311D0 (en) Processes for the preparation of compounds